How to Read Health Research News
A plain-language checklist for judging dementia and memory headlines, from mouse studies and small samples to "percent slowing" and "time saved" claims, so you can tell real progress from hype.
Last reviewed: October 2026
"Breakthrough." "Cure." "This one food cuts your risk in half." Dementia research makes headlines almost every day, and much of it is genuinely exciting. But a headline is not a study. Here's a practical checklist for reading health news without getting misled.
1. Who was studied: mice, cells or people?
Many headlines come from studies in mice, cells or tissue in a dish. These are important early steps, but most treatments that work in mice never work in people. Mice don't naturally get Alzheimer's; researchers engineer them to develop some of its features.
If the story doesn't say "in people" or "in patients," look for the words mice, animal model, lab or cells. Treat these findings as "interesting, check back in ten years."
2. What kind of study was it?
- Observational studies follow groups of people and look for links, such as "people who walk more get dementia less often." They can't prove cause and effect. Healthier, wealthier or more educated people may both walk more and have lower risk for other reasons. Researchers try to adjust for these, but they can't catch everything.
- Randomized controlled trials randomly assign people to a treatment or a comparison (often a placebo). Randomization balances out hidden differences, so these trials are much better at showing whether something actually causes a benefit.
- Reviews and meta-analyses combine many studies. They carry more weight than any single study, as long as the studies they combine are good.
Watch the verbs. "Linked to," "associated with" and "tied to" usually signal an observational study. "Reduced" or "prevented" should come from a trial.
3. How big and how long?
A study of 30 people for 12 weeks can be a useful start, but its results often don't hold up in bigger studies. Dementia develops over years, so short studies can only measure short-term changes on tests, not whether people actually avoided dementia.
4. What exactly was measured?
Ask whether the study measured something that matters in daily life, such as staying independent, avoiding a dementia diagnosis or quality of life, or a stand-in measure such as a blood marker, a brain scan or a score on a thinking test. Stand-in measures can be useful, but they don't always translate into real-world benefit.
The A4 prevention trial is a good example: the drug solanezumab slowed the build-up of amyloid on brain scans compared with placebo, but it did not slow decline in thinking (see Prevention Trials).
5. How big was the effect, really?
"Cuts risk by 50%" sounds huge. But if your risk was 2 in 100 and drops to 1 in 100, that's a 50% relative reduction and a 1-point absolute reduction. Look for the actual numbers.
Alzheimer's drug news has its own version of this. Trials report results on rating scales that are hard for non-specialists to interpret, so results are often translated into "slowed decline by 27%" or "about six months of time saved." In October 2026, researchers at University College London warned that these translations can unintentionally exaggerate benefits. "Time saved" figures come from statistical modeling, not from directly watching people stay independent longer, and they shouldn't be read as extra months of independence or quality of life. Our pages on Lecanemab (Leqembi) and Donanemab (Kisunla) explain what the trials directly measured.
6. What were the downsides?
Every real treatment has trade-offs. Good reporting mentions side effects, cost, how many people dropped out and who the treatment is not for. If an article mentions only benefits, be suspicious.
7. Who paid, and who is talking?
Funding by a company doesn't make a study wrong, but it's worth knowing. Be especially careful with:
- Articles that end in a product link or a "limited-time offer"
- Supplement ads that cite "clinically studied ingredients" without naming the study (see Supplements and Memory Claims)
- Quotes only from the study's own authors, with no outside expert
8. Has it been published and checked?
Results presented at a conference or posted as a "preprint" haven't yet gone through full peer review. That doesn't make them wrong, but they're more likely to change. A press release is written to get attention; the study itself is where the limits are listed.
A quick checklist
Before you change anything based on a headline, ask:
- Was it in people?
- Was it a randomized trial or an observational study?
- How many people, and for how long?
- Did it measure something that matters in daily life?
- What are the absolute numbers, not just percentages?
- What were the risks and costs?
- Do other studies agree?
Where to find trustworthy information
The National Library of Medicine's MedlinePlus has a short guide to evaluating health information online. The National Institute on Aging and the Alzheimer's Association explain research in plain language. On this site, our Dementia Research Today summarizes where dementia science stands, and our daily updates flag early-stage findings clearly.
The bottom line
Most single studies are a step, not an answer. Exciting early results are worth following, but decisions about your health are best made with your doctor, based on strong evidence from trials in people. Never stop a prescribed medicine because of a headline.
Sources
- MedlinePlus (U.S. National Library of Medicine): Evaluating Health Information
- UCL Faculty of Brain Sciences: UCL researchers call for greater caution when describing the benefits of Alzheimer's treatments (October 2026)
- Sperling RA et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. New England Journal of Medicine, 2023
Not medical advice. This article is general information, not a diagnosis or treatment plan for any individual. Talk with a doctor about your situation.
Related articles
- Dementia Research Today
- Joining a Clinical Trial
- Supplements and Memory Claims
- Lecanemab (Leqembi)
- Donanemab (Kisunla)
Ask a question
Have a question about memory, Alzheimer's, or caregiving? Email us at:
Open in my email app · Write in Gmail (opens in a new tab)
We may answer common questions in future updates (we won't share your name). We can't give personal medical advice; for urgent help call the Alzheimer's Association Helpline at 800-272-3900.